




CFA-injected paws exhibit decreased paw withdrawal latency compared to non-injected paws




Repeated injections of BNN27 100 mg/kg after the induction of inflammation did not have any effect on paw withdrawal latency



Single injection of BNN27 100 mg/kg after the induction of inflammation did not have any effect on paw withdrawal latency



BNN27 administration did not change IL-1 β protein levels at any time point and route of administration examined



Serum corticosterone levels remained unchanged following repeated injections of BNN27 100 mg/kg at 6 hours




Figure S1: Effect of different doses of BNN27 on paw withdrawal latencies, IL-1 β and corticosterone levels (6hrs).




Figure S2: Effect of repeated injections of BNN27 10 mg/Kg on cytokine levels in the inflamed paw and blood at 3 hours post CFA injections.




Figure S3: Effect of a single injection of BNN27 100 mg/kg on cytokine levels in the inflamed paw and blood at 3 hours post CFA injections




Figure S4: Repeated injections of BNN27 100 mg/kg did not affect AKT1 signaling pathway




Figure S5: mRNA levels of TrkA receptor p75 and substance p remained unaffected by BNN27 treatment




Figure S6: Administration of BNN27 100 mg/kg simultaneously with TrkA inhibitor did not affect μ -opioid receptor and PENK mRNA compared to mice treated only with BNN27